Skip to main content
49°
Rain
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Absci Corp
(NQ:
ABSI
)
2.550
-0.130 (-4.85%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Absci Corp
< Previous
1
2
3
Next >
Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference
Today 8:00 EST
From
Absci Corporation
Via
GlobeNewswire
Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results
November 12, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci to Host R&D Day on December 12, 2024
November 07, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
October 31, 2024
Collaboration brings together Absci’s Generative AI drug creation platform with Twist’s DNA synthesis platform to accelerate the design of a novel therapeutic antibody
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
October 24, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024
October 15, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
August 21, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results
August 14, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI
August 12, 2024
The collaboration unites Absci’s Generative AI Drug Creation Platform with leading oncology experts to co-develop up to six novel cancer therapeutics
From
Absci Corporation
Via
GlobeNewswire
Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024
July 10, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit
June 12, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 28, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
May 14, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024
April 16, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference
March 28, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
March 21, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
March 01, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci Announces Pricing of Public Offering of Common Stock
February 27, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci Announces Proposed Public Offering of Common Stock
February 27, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI
February 21, 2024
IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
February 20, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
January 10, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the 26th Annual Needham Growth Conference
January 03, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 28, 2023
From
Absci Corporation
Via
GlobeNewswire
Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline
December 20, 2023
From
Absci Corporation
Via
GlobeNewswire
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
December 04, 2023
Collaboration Combines Absci’s AI Antibody Drug Creation Platform with AstraZeneca’s Expertise in Oncology Research and Development
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the Piper Sandler 35th Annual Healthcare Conference
November 15, 2023
From
Absci Corporation
Via
GlobeNewswire
Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results
November 14, 2023
From
Absci Corporation
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.